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Summary Cathespin D (Cath D) is a proteolytic enzyme secreted by human breast cancer cells with a growth
promoting activity in vitro. In the present study, we measured Cath D and Epidermal Growth Factor/alpha
Transforming Growth Factor (EGF/o-TGF) concentrations in the breast cyst fluid (BCF) of 43 patients with
gross cystic disease of the breast. Both Cath D (median 2.45 pmolesmg-I protein; range 0-4.84 vs 0.98
pmoles mg- I protein; range 0-3.11) and EGF/a-TGF (28.71 ng mg-' protein; range 7.05-50.63 vs 10.83 ng
mg-I protein; range 0.06-30.55) levels were higher in BCF of apocrine than flattened cysts (P<0.0005 and
P<0.01, respectively). Premenopausal patients showed higher concentrations of Cath D (P<0.05) and
EGF/a-TGF (P 0.05) than postmenopausal patients. A positive correlation was obtained between intracystic
concentrations of Cath D and EGF/a-TGF (P<0.00001). The higher levels of Cath-D and EGF/a-TGF
found in apocrine cysts could provide an explanation for the increased risk of subsequent breast cancer in
women with this type of cyst.
Although the data are not univocal (Page et al., 1978; Du-
pont et al., 1985), several studies suggest that women with
gross cystic disease have a greater risk of developing breast
cancer (Haagensen et al., 1981). These cysts are lined by
apocrine or flattened epithelium, the former being at greater
risk of neoplastic transformation (Haagensen et al., 1981;
Dixon et al., 1985). Because of these observations, breast cyst
fluid (BCF) which is easily obtainable from cysts by aspira-
tion, has been extensively investigated in order to identify
specific biochemical features related to cyst evolution (Brad-
low et al., 1981; Jaspar et al., 1980; Boccardo et al., 1988;
Battaglia et al., 1989; Hamed et al., 1990; Lai et al., 1990).
The concentrations of electrolytes in BCF has been shown to
be correlated with the pathohistology of the breast (Dixon et
al., 1985). Moreover we (Battaglia et al., 1989) and others
(Jaspar et al., 1980; Boccardo et al., 1988; Hamed et al.,
1990; Todaro et al., 1980) reported that BCF contain large
amounts of Epidermal Growth Factor (EGF), which has a
mitogenic effect on normal and neoplastic breast cells in vitro
and seems to be involved in the autocrine regulation of
breast cancer in vivo (Todaro et al., 1980; Osborne et al.,
1980; Taketani et al., 1983). The finding that higher EGF
concentrations are present in apocrine than flattened cysts
have suggested that this growth factor may be involved in
mammary carcinogenesis (Boccardo et al., 1988; Battaglia et
al., 1989; Hamed et al., 1990; Lai et al., 1990). Garcia et al.
(1986) reported that BCF also contain varying concentrations
of a Mr 52,000 (52K) secreted protein induced by oestrogen
in MCF-7 cells (Westley et al., 1979). This protein has been
identified as pro-Cath-D, a proteolytic enzyme which displays
a mitogenic effect in vitro (Vignon et al., 1986; Morisset et
al., 1986; Briozzo et al., 1988).
Since at present no data concerning the concentration of
Cath D in different cyst types are available, we have studied
its distribution in several BCF, and results have been cor-
related with EGF levels and cytological findings.
Materials and methods
BCF was obtained by needle aspiration from 27 women
ofpre-menopausal status (median age 41 years, range 23-48)
and 16 of post-menopausal status (median age 52 years,
range 46-67). All patients were classified as having gross
cystic disease (GCD) according to Haagensen et al. (1981)
and the size of cysts was determined by ultrasonography
(General Electric RT 3600). Cystic volume was measured
according to the formula for an ovoid sphere n x 1/6
(length x width x depth). The cyst fluid aspirates were centri-
fuged at 2,000g at 4'C. The cellular material was stained by
PAP technique and by periodic acid-shift for cytologic exam-
ination. The supranatant was aliquoted and stored at - 20'C
until the assay.
Cath-D concentration was assayed using a solid phase two
site immunoradiometric assay (CIS bioindustries, Gift-sur-
Yvette, France) in which the first monoclonal antibody
(D7E3) is coated on the ELISA solid phase and the second
one, M1G8, radiolabelled with 125I is used as a tracer (Brou-
illet et al., 1990; Scambia et al., 1991). For the Cath-D assay,
cytosol protein concentration measured by the Bradford
method (Bradford et al., 1976) was reset to about 1 mgml-I
before the assay. Cytosols were then diluted 1/40 and 1/80
with the diluent contained in the kit. Radioactivity was
measured in a 'y-counter for 1 min. Intra- and inter-assay
variations were 6.4% and 8.5%, respectively.
The EGF assay was performed by a radio-receptor assay
based on the competitive protein binding, using membrane
receptor particles as the binding protein and an "25I labelled
EGF peptide (Amersham Int, Holland) (Battaglia et al.,
1989). This radio receptor assay permits the evaluation of the
presence of EGF as well as of EGF-like substances which are
able to interact with EGF receptor, i.e. a-Transforming
Growth Factor (a-TGF). Results were expressed as ngmg-'
protein of EGF/a-TGF.
The Wilcoxon's rank sum test was used to compare distri-
bution between the two cyst groups. Correlation coefficients
were calculated using Spearman's rank correlation method.
Results
Figure 1 shows the distribution of Cath D levels according
to the cyst type. Cath D concentration was higher in apo-
crine (median 2.45 pmoles mg'- protein, range 0-4.84) than
flattened (median 0.98pmoles mg-' protein, range 0-3.11)
cysts (P<0.0005). This difference also persisted when
patients were divided according to the menopausal status.
Among premenopausal patients the median Cath D content
was 2.66 pmoles mg'l protein and 1.50 pmoles mg-' protein
for apocrine and flattened cysts (P<0.01), while for post-
menopausal patients the respective values were 1.70 pmoles
mg'I protein and 0.69 pmoles mg-' protein (P<0.05). Over-
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Figure 2 Correlation between Cath D and EGF/a-TGF concent-
rations in human breast cyst fluid. The correlation coefficient was
0.81 (P<0.00001) for the overall population and 0.80
(P<0.00001) and 0.61 (P<0.005) for apocrine (0) and flatten-
ed (0) cysts, respectively.
in flattened cysts this difference was not statistically signi-
ficant.
Both in apocrine and flattened cysts there was a highly
significant correlation between Cath D and EGF/a-TGF
levels (Figure 2). No correlation were found between the
concentrations of Cath D or EGF/a-TGF and cyst volume
(data not shown).
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Figure 1 Distribution of Cath-D and EGF/a-TGF according to
breast cyst type. (0), premenopausal patients; (0) post-meno-
pausal patients. The horizontal lines represent median concentra-
tions.
all Cath D levels were higher in premenopausal than in
postmenopausal patients (P<0.05). In particular, apocrine
cysts in premenopausal patients showed a significantly higher
Cath D content (median= 2.66 pmolesmg-' protein; range
0-4.64) with respect to apocrine cysts in postmenopausal
patients (median 1.84 pmolesmg-' protein; range 0.96-3.00)
(P<0.05). In flattened cysts a trend toward higher Cath D
levels in premenopausal (median = 1.50pmolesmg-' protein;
range 0-3.11) than in postmenopausal patients (median=
0.69 pmolesmg-' protein; range 0-2.34) was found, although
the difference did not reach statistical significance. Among
patients of reproductive age, no different Cath D concentra-
tions were found in the BCF obtained in the follicular and in
the luteal phases of cycle (data not shown).
The distribution of EGF/a-TGF values closely resembled
that previously described by us (Battaglia et al., 1989) and
others (Boccardo et al., 1988; Hamed et al., 1990; Lai et al.,
1990), with higher values in apocrine (median 28.71 ngml -
protein, range 7.05-50.63) than flattened (median 10.83 ng
mg' protein, range 0.06-30.55) cysts (P<0.01) and in pre-
menopausal (median 20.85 ngmg' protein, range 0.06-50.63)
with respect to postmenopausal (median 13.88 ngmg' pro-
tein, range 0.06-30.55) (P<0.05) patients. Likewise for Cath
D values, among apocrine cysts EGF/a-TGF content was
higher in premenopausal (median = 32.17 ngmg-' protein;
range 13.32-50.63) than in postmenopausal (median = 18.66
ngmg' protein; range 7.05-29.77) (P<0.05) patients while
Discussion
Cath D, a lysosomal aspartyl endopeptidase secreted by
human breast cancer cells, displays a mitogenic effect in vitro
(Vignon et al., 1986) and a proteolytic effect on extracellular
matrix after its autoactivation at acidic pH (Briozzo et al.,
1988). In breast cancer, a high cytosolic concentration of
Cath D is associated with a shorter relapse-free survival
(Brouillet et al., 1990).
Results reported here indicate that ranging concentrations
of Cath D are present in BCF. This is a further demonstra-
tion that BCF contain substances which may be involved in
the autocrine and/or paracrine regulation of the proliferation
of breast cyst epithelium (Jaspar et al., 1980; Boccardo et al.,
1988; Battaglia et al., 1989; Wang et al., 1989; Hamed et al.,
1990; Lai et al., 1990).
The most interesting finding of this study is that Cath D
concentrations were higher in apocrine than flattened cysts,
since patients with apocrine cysts are those with higher risk
of developing breast cancer. This is consistent with a pre-
vious study by Garcia et al. (1986) who reported that the
immunohistochemical evaluation of 52K is a potential tissue
marker for distinguishing high-(proliferative) from low-risk
(non proliferative) benign breast disease.
Interestingly, the values of EGF/x-TGF showed a distribu-
tion similar to that of Cath D. This finding was in keeping
with our previous study (Battaglia et al., 1989) and with
three other reports (Boccardo et al., 1988; Hamed et al.,
1990; Lai et al., 1990). It can be suggested that an increased
production of mitogenic substances such as Cath D and
EGF/a-TGF may be associated with the early stages of
mammary carcinogenesis. It is also conceivable that Cath D
and EGF may cooperate in the promotion of breast cell
proliferation. As for other proteases, Cath D may act
indirectly by releasing growth factors, such as ox-TGF from
precursors or from extracellular matrix and/or by activating
growth factor receptors (Derynck et al., 1984; Lawrence et
al., 1985).
A positive correlation has been found between intracystic
concentrations of Cath D and EGF/a-TGF. This is in agree-
ment with the finding that in human breast and endometrial
cancer cells Cath D is regulated at the mRNA level by EGF
(Cavailles et al., 1988). Alternatively it is possible that a
common stimulus might be responsible for the elevating
levels of Cath D and EGF/a-TGF. As a matter of fact in
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human breast cancer cells oestrogen modulate the secretion
of Cath D (Westley et al., 1979; Vignon et al., 1986; Morisset
et al., 1986) and a-TGF (Dickson et al., 1986). The finding of
higher levels of both substances in BCF in premenopausal
women with respect to postmenopausal women, suggest that
sex steroid hormones might be involved in the growth pep-
tide production by cystic epithelium of the breast.
In conclusion, our study indicates that BCF contains Cath
D and that this enzyme, together with EGF/a-TGF may have
a role in the proliferative pathology of the breast. The solu-
tion to this problem will come from a prospective study of
patients with gross cystic disease.
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